Compare BFRI & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFRI | BMRA |
|---|---|---|
| Founded | 1997 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.2M |
| IPO Year | 2021 | N/A |
| Metric | BFRI | BMRA |
|---|---|---|
| Price | $0.74 | $2.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | 89.8K | ★ 141.9K |
| Earning Date | 11-12-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,164,000.00 | $4,884,000.00 |
| Revenue This Year | $9.70 | N/A |
| Revenue Next Year | $10.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.11 | N/A |
| 52 Week Low | $0.54 | $2.11 |
| 52 Week High | $1.87 | $10.16 |
| Indicator | BFRI | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 62.89 |
| Support Level | $0.70 | $2.30 |
| Resistance Level | $0.82 | $2.85 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 10.71 | 72.73 |
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.